<DOC>
	<DOCNO>NCT01818908</DOCNO>
	<brief_summary>The major purpose clinical study assess clinical outcome dose-adjusted EPOCH regimen patient non-Hodgkin 's lymphoma ( NHL ) -associated hemophagocytic lymphohistiocytosis</brief_summary>
	<brief_title>Trial DA-EPOCH Regimen NHL With HLH</brief_title>
	<detailed_description>Lymphoma-associated hemophagocytic lymphohistiocytosis ( LA-HLH ) high fatality rate bad outcome . The major cause LA-HLH aggressive non-Hodgkin 's lymphoma ( NHL ) , especially T/NKT cell lymphoma . Until , recommend therapeutic schedule fatal disease . Dose-adjusted ( DA ) EPOCH ( etoposide , prednisone , vincristine , cyclophosphamide , doxorubicin ) show effective activity patient aggressive NHL . The investigator therefore develop DA-EPOCH regimen treat non-Hodgkin 's lymphoma hemophagocytic lymphohistiocytosis assess clinical outcome include safety efficacy .</detailed_description>
	<mesh_term>Lymphohistiocytosis , Hemophagocytic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>1 . Histologically confirm nonHodgkin 's lymphoma ; 2 . Patients whose clinical finding satisfy either HLH 2004 standard ASH2009 standard : HLH2004 standard least 5 criterion follow : Fever ≥ 38.5 ℃ ≥ 7 day ; hepatosplenomegaly ; Cytopenias affect ≥ 2 3 lineage PB Hb &lt; 9 g/L Platelet &lt; 100 x 109 /L ANC &lt; 1.0 x 109 /L ; Hypertriglyceridemia and/or hypofibrinogenemia ( fast triglyceride ≥ 265 mg/dL , fibrinogen ≤ 1.5 g/L ) ; Hemophagocytosis BM spleen LN ; Low absent NKcell activity ( accord local laboratory reference ) ; Serumferritin ≥ 500 mcg/L ; Soluble CD25 ( sIL2 receptor ) ≥ 2,400 U/ml ; 3 . Newdiagnosed untreated ; 4 . Understand voluntarily sign informed consent form , able adhere study visit schedule protocol requirement . ASH2009 Standard 1 . .At least 3 4 : 1 . Fever 2 . Splenomegaly 3 . Cytopenias ( minimum 2 cell line reduce ) 4 . Hepatitis 2. . And least 1 4 : 1 . Hemophagocytosis 2 . ↑ Ferritin 3 . ↑ sIL2Rα ( age base ) 4 . Absent decrease NK function 4 . Other result supportive HLH diagnosis : 1 . Hypertriglyceridemia 2 . Hypofibrinogenemia 3 . Hyponatremia 1 . Primary HLH . 2 . HLH rheumatic disorder ( SLE , AOSD , antiphospholipid antibody syndrome ) 3 . Pregnancy ( determine serum urine test ) active breast feeding 4 . Concomitant malignancy nonHodgkin 's lymphoma need treat ; 5 . Concomitant hematologic disease ( leukemia , hemophilia primary myelofibrosis ) investigator unsuitable enrol clinical trial ; 6 . Any potential drug abuse , medical , psychological social condition may disturb investigation assessment . 7 . In condition investigator consider ineligible study .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>non-Hodgkin 's lymphoma</keyword>
	<keyword>hemophagocytic lymphohistiocytosis</keyword>
	<keyword>DA-EPOCH</keyword>
	<keyword>rituximab</keyword>
</DOC>